Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C

被引:91
|
作者
Caballero, T
Pérez-Milena, A
Masseroli, M
O'Valle, F
Salmerón, FJ
Del Moral, RMG
Sánchez-Salgado, G
机构
[1] Univ Granada, Sch Med, Dept Pathol, Granada 18012, Spain
[2] Univ Granada, Univ Hosp, Granada 18012, Spain
[3] Univ Granada, Sch Med, Dept Internal Med, Granada 18012, Spain
关键词
hepatitis C; liver fibrosis; image analysis; automatic quantification; Knodell activity index; Scheuer activity grade; Knodell fibrosis scoring; Scheuer fibrosis staging; interferon;
D O I
10.1016/S0168-8278(01)00006-X
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: The effect of interferon on the reduction of liver fibrosis is controversial. We aimed to compare semiquantitative methods with a quantitative digital image analysis system to assess liver fibrosis in biopsies from patients with chronic hepatitis and different responses to interferon, Methods: We studied 98 liver biopsies with chronic hepatitis C before and after recombinant interferon alfa-2 treatment, using conventional histological assessment, grading of histological activity, scoring/staging of fibrosis (Knodell and Scheuer), and quantification of fibrosis with image analysis (FibroQuant). Results: Sustained-responders to interferon showed a significant reduction in histological lesions and in their Knodell and Scheuer activity indexes. The semiquantitative systems showed no reduction in fibrosis, The FibroQuant application showed a significant reduction in porto-periportal and septal areas among sustained-responders (P < 0.001) and non-responders (P < 0.05), and in porto-periportal and septal fibrosis areas only in sustained-responders (P < 0.001), whereas the percentage of fibrosis increased in non-responders (P < 0.001). Conclusions: The Scheuer system is useful for the daily evaluation of fibrosis, but the FibroQuant application provides more objective data on the anti-fibrogenic effects of interferon, which include a reduction in the portoperiportal area in sustained-responders and non-responders, accompanied by a reduction in the area of fibrosis only when the viral replication has ceased. (C) 2001 European Association for the Study of the Liver. Published by Elsevier Science B,V, All rights reserved.
引用
收藏
页码:740 / 747
页数:8
相关论文
共 50 条
  • [21] Eradication of hepatitis C virus after 3 months of interferon and ribavirin treatment in an α interferon non-responder patient with chronic hepatitis C
    Hrycewycz, N
    Sandres, K
    Barange, K
    Pascal, JP
    Izopet, J
    Payen, JL
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2001, 25 (11): : 1041 - 1042
  • [22] Daily use of ribavirin-interferon combination in earlier non-responder or relapser patients with chronic hepatitis C.
    Karasu, Z
    Gurakar, A
    Jazzar, A
    McMillon, G
    Hulagu, S
    Wright, H
    HEPATOLOGY, 1999, 30 (04) : 629A - 629A
  • [23] Amantadine plus interferon is not effective in non responder to interferon chronic hepatitis C patients.
    Diago, M
    Perez-Anton, C
    García, V
    Carbonell, P
    Cors, R
    Aznar, V
    Martinez, M
    Andreu, J
    HEPATOLOGY, 1999, 30 (04) : 629A - 629A
  • [24] CHANGES IN ELF SCORE DURING TREATMENT WITH PEGYLATED INTERFERON AND SILYMARIN ARE ASSOCIATED WITH PROGRESSION OF HISTOLOGICAL LIVER DISEASE IN NON-RESPONDER PATIENTS WITH CHRONIC HEPATITIS C
    Tanwar, S.
    Ellis, E.
    Parkes, J.
    Herold, C.
    Rosenberg, W.
    GUT, 2011, 60
  • [25] Interferon alpha plus ribavirin tor chronic hepatitis C genotype 1b non-responder patients to interferon alone.
    Iacono, OL
    Castro, A
    Diago, M
    Cors, R
    Borque, MJ
    Buey, LG
    Monzon, CG
    Pedreira, J
    Otero, RM
    HEPATOLOGY, 1999, 30 (04) : 266A - 266A
  • [26] Structural studies of Helicase NS3 variants from Hepatitis C virus genotype 3 in virological sustained responder and non-responder patients
    Provazzi P.J.S.
    Arcuri H.A.
    De Carvalho-Mello I.M.V.G.
    Pinho J.R.R.
    Nogueira M.L.
    Palma M.S.
    Rahal P.
    BMC Research Notes, 3 (1)
  • [27] Interferon plus ribavirin in interferon non-responder or relapsing chronic hepatitis C patients:: End of treatment response and sustained response at third follow-up month.
    Moreno-Monteagudo, JA
    García-Buey, L
    Fernández-Bermejo, M
    Sanz, P
    Borque, MJ
    Lo Iacono, O
    García-Monzón, C
    Moreno-Otero, R
    HEPATOLOGY, 1998, 28 (04) : 476A - 476A
  • [28] Changes in ELF Score During Treatment With Pegylated Interferon and Silymarin Are Associated With Progression of Histological Liver Disease in Non-Responder Patients With Chronic Hepatitis C
    Tanwar, Sudeep
    Ellis, Elizabeth L.
    Parkes, Julie
    Herold, Christoph
    Rosenberg, William M.
    GASTROENTEROLOGY, 2011, 140 (05) : S979 - S979
  • [29] GGT/ALT ratio is related to serum markers of fibrosis and predict sustained response to interferon (IFN) plus ribavirin (RBV) in non-responder/relapser patients with chronic hepatitis (CHC)
    Moreno-Monteagudo, JA
    Majano, P
    Borque, MJ
    Garcia-Buey, L
    Garcia-Monzon, C
    Moreno-Otero, R
    JOURNAL OF HEPATOLOGY, 2001, 34 : 125 - 126
  • [30] Low dose ribavirin (RBV) in combination interferon (IFN) for the treatment of hepatitis C non-responder and relapse patients
    Bernstein, DE
    Jeffers, LJ
    Lake-Bakaar, G
    Reddy, KR
    Schiff, ER
    GASTROENTEROLOGY, 1999, 116 (04) : A1190 - A1190